Anthracycline-free versus anthracycline-based neoadjuvant therapy in HER2-positive breast cancer: A Propensity score-matched real-world study.
- DOI
- 10.1016/j.ctarc.2026.101429
- Published
- 2026 Sep 22
- Container
- Cancer treatment and research communications
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ctarc.2026.101429,
title = {Anthracycline-free versus anthracycline-based neoadjuvant therapy in HER2-positive breast cancer: A Propensity score-matched real-world study.},
author = {Sharaf B and Tamimi F and Alzoubi M and Jawarneh Q and Ismail A and Ghanem A and Ata JB and Ajlouni B and Khader R and Jaffal A and Khater S and Jehad S and Abdel-Razeq H},
year = {2026},
journal = {Cancer treatment and research communications},
doi = {10.1016/j.ctarc.2026.101429},
url = {https://doi.org/10.1016/j.ctarc.2026.101429}
}RIS
TY - JOUR TI - Anthracycline-free versus anthracycline-based neoadjuvant therapy in HER2-positive breast cancer: A Propensity score-matched real-world study. AU - Sharaf B AU - Tamimi F AU - Alzoubi M AU - Jawarneh Q AU - Ismail A AU - Ghanem A AU - Ata JB AU - Ajlouni B AU - Khader R AU - Jaffal A AU - Khater S AU - Jehad S AU - Abdel-Razeq H PY - 2026 JO - Cancer treatment and research communications DO - 10.1016/j.ctarc.2026.101429 UR - https://doi.org/10.1016/j.ctarc.2026.101429 ER -
APA
B, S., F, T., M, A., Q, J., A, I., A, G., JB, A., B, A., R, K., A, J., S, K., S, J., & H, A. (2026). Anthracycline-free versus anthracycline-based neoadjuvant therapy in HER2-positive breast cancer: A Propensity score-matched real-world study.. Cancer treatment and research communications. https://doi.org/10.1016/j.ctarc.2026.101429
Source records
- pubmed · retrieved 2026-09-27T10:02:34.901Z